Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 sept. 2023 07h03 HE | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023

Data presentations explore effects on patient-centric efficacy measures of treatments for patients with depression, and excessive sleepiness associated with obstructive sleep apnea and narcolepsy NEW...
25 août 2023 06h00 HE | Source: InvestmentPitch Media & MindBio Therapeutics

InvestmentPitch Media Video Discusses MindBio Therapeutics' Commencement of MB22001 Phase 2 Clinical Trial in World's First Take-Home Microdosing Study for Patients with Depression

VANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) (FSE:WF6), an Australia-based biotech/biopharma company creating novel and emerging treatments for...
30 mai 2023 07h00 HE | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Data on Auvelity demonstrating improved functioning in major depressive disorder Data on Sunosi demonstrating improved cognitive function in patients with excessive daytime sleepiness associated with...
04 mai 2023 08h30 HE | Source: ABVC BioPharma, Inc.

ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder

FREMONT, CA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
20 oct. 2022 07h00 HE | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week1-4 ...
14 févr. 2022 02h00 HE | Source: Nexstim Oyj

Nexstim Abp licensierar ut teknik till det amerikanska medicinteknikföretaget Magnus Medical, Inc. för behandling av neuropsykiatriska tillstånd

Företagsmeddelande, insiderinformation, Helsingfors 14.2.2022 kl. 9.00 (EET) Nexstim Abp licensierar ut teknik till det amerikanska medicinteknikföretaget Magnus Medical, Inc. för behandling av...
14 févr. 2022 02h00 HE | Source: Nexstim Oyj

Nexstim Oyj lisensoi kehittämäänsä teknologiaa yhdysvaltalaiselle lääkintäteknologiayhtiö Magnus Medical, Inc.:ille käytettäväksi neuropsykiatrisien häiriöiden hoitoon

Yhtiötiedote, sisäpiiritieto, Helsinki, 14.2.2022 klo 9.00 (EET) Nexstim Oyj lisensoi kehittämäänsä teknologiaa yhdysvaltalaiselle lääkintäteknologiayhtiö Magnus Medical, Inc.:ille käytettäväksi...
14 févr. 2022 02h00 HE | Source: Nexstim Oyj

Nexstim Plc to license technology to US-based medical technology company Magnus Medical, Inc. for the treatment of neuropsychiatric disorders

Company Announcement, Inside Information, Helsinki, 14 February 2022, at 9 AM (EET) Nexstim Plc to license technology to US-based medical technology company Magnus Medical, Inc. for the treatment of...
22 nov. 2021 02h00 HE | Source: Nexstim Oyj

Nexstim on sopinut strategisesta investoinnista masennuspotilaille hoitoja tarjoavaan kalifornialaisen klinikan palveluyhtiöön

Yhtiötiedote, sisäpiiritieto, Helsinki, 22.11.2021 klo 9.00 (EET) Nexstim on sopinut strategisesta investoinnista masennuspotilaille hoitoja tarjoavaan kalifornialaisen klinikan palveluyhtiöön ...
22 nov. 2021 02h00 HE | Source: Nexstim Oyj

Nexstim Agrees on a Strategic Investment into a Management Services Organisation of a California Based Clinic Providing Treatments for Depression Patients

Company Announcement, Inside information, Helsinki, 22.11.2021 at 9 AM (EET) Nexstim Agrees on a Strategic Investment into a Management Services Organisation of a California Based Clinic Providing...

Page précédente

Page suivante